current therapeutic regimen for visceral leishmaniasis is inadequate and unsatisfactory due to toxic side effects, high cost and emergence of drug resistance. Alternative, safe and affordable antileishmanials are, therefore, urgently needed and toward these we synthesized a series of arylpiperazine substituted pyranone derivatives and screened them against both in vitro and in vivo model of visceral
目前内脏利什曼病的治疗方案由于毒副作用、成本高和耐药性的出现而不足且不能令人满意。因此,迫切需要替代、安全和负担得起的抗利什曼原虫,为此我们合成了一系列芳基
哌嗪取代的
吡喃酮衍
生物,并针对内脏利什曼病的体外和体内模型对其进行了筛选。在合成的 22 种化合物中,5a和5g对细胞内无鞭毛体表现出更好的活性,IC 50 分别为 11.07 μM 和 15.3 μM。在体内,5a显着降低了内脏利什曼病 Balb/c 小鼠模型中肝和脾无鞭毛体的负担。在机械节点上,我们观察到5a通过线粒体功能障碍(如细胞色素c释放和膜电位丧失)诱导直接杀死利什曼原虫。总之,我们的结果表明5a是进一步开发抗利什曼病药物的有希望的先导。